Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 14/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945250 | 0.88 | F2R (0.44) | F2RF2LCKKLKB1 | |
| SCHEMBL12340166 | 0.84 | KLKB1 (0.41) | F2RLCKKLKB1 | |
| SCHEMBL12340155 | 0.84 | F2R (0.67) | F2RF2 | |
| SCHEMBL13945253 | 0.82 | F2R (0.74) | F2RF2 | |
| SCHEMBL12340177 | 0.81 | F2R (0.63) | F2RF2 | |
| SCHEMBL12340158 | 0.80 | F2R (0.65) | F2RF2 | |
| SCHEMBL14583980 | 0.78 | F2R (0.57) | F2RF2KLKB1 | |
| SCHEMBL12340129 | 0.77 | F2R (0.65) | F2RF2 | |
| SCHEMBL12340171 | 0.76 | F7 (0.43) | F2RLCKKLKB1 | |
| SCHEMBL12340161 | 0.75 | F2R (0.56) | F2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | F2R 2/4885F2 16/4885ALOX5 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.